Neuren Pharmaceuticals Limited

NEU

Neuren Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment, and neurodegenerative disorders. The company is headquartered in Melbourne, Victoria. The company went IPO on 2005-02-03. The firm is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. The Company’s product DAYBUE (trofinetide) is used to treat Rett syndrome in adults and pediatric patients two years of age and older. The United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation to the Company for trofinetide in Fragile X syndrome. Its second product NNZ-2591 is in phase II clinical trials in Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. The firm has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of NNZ-259 for Rett syndrome and Fragile X syndrome.

Droneshield Limited

DRO

DroneShield Ltd. engages in the development and commercialisation of hardware and software technology for drone detection and security. The company is headquartered in Sydney, New South Wales. The company went IPO on 2016-06-22. The company provides artificial intelligence-based platforms for protection against advanced threats, such as drones and autonomous systems. The company offers customers bespoke counter-drone (or counter-UAS) and electronic warfare solutions and off-the-shelf products designed to suit a variety of terrestrial, maritime, or airborne platforms. The Company’s products include DroneGun Tactical, DroneGun MKIII, DroneSentry, DroneSentry-C2, DroneSentry-X, RfPatrol and DroneSim among others. The DroneGun Tactical is an unmanned aerial systems (UAS) countermeasure designed for two-hand operation and long-range defeat. RfPatrol is a passive/non-emitting wearable UAS detection device. The Company’s capabilities include C-UAS, C-UxS Training, and Electronic Warfare.

Aeris Resources Limited

AIS

Aeris Resources Ltd. engages in the production, exploration, and sale of copper, gold and silver. The company is headquartered in Brisbane, Queensland. The company went IPO on 2011-02-02. The company is engaged in the production, sale and exploration of copper, zinc, gold and silver. Its segments include Tritton Copper Operations; Cracow Gold Operations; North West Copper Operations; Jaguar Zinc and Copper Operations; Stockman Copper and Zinc Project, Other. Tritton Copper Operations is an underground copper operation located in the Cobar region of central New South Wales. Cracow Gold Operations is an underground gold operation located in central Queensland. Jaguar Operations is an underground zinc, copper and silver mining operation located in the Eastern Goldfields region of Western Australia. North Queensland Operations comprises of underground Mt Colin copper mine, Barbara development project and a prospective, 1,102 square kilometers (km2) tenement package. The Stockman Copper and Zinc Project is a copper and zinc development project located 300 kilometers (km) northeast of Melbourne.

Betashares Australia 200 ETF

A200

A200.AX was created on 2018-05-07 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The ETF currently has 7314.93m in AUM and 198 holdings. A200.AX aims to track the performance of an index (before fees and expenses) comprising 200 of the largest companies by market capitalisation listed on the ASX.

Betashares Asia Technology Tigers ETF

ASIA

ASIA.AX was created on 2018-09-18 by BetaShares. The fund's investment portfolio concentrates primarily on information technology equity. The investment objective of the BetaShares Asia Technology Tigers ETF is to provide an investment return that aims to track the performance of the Solactive Asia ex-Japan Technology & Internet Tigers Index (the Index), before taking into account fees and expenses.